TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93 | -41.5% | 10,383 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $159 | -15.4% | 10,383 | +23.9% | 0.00% | -50.0% |
| Q1 2023 | $188 | -6.9% | 8,379 | -12.8% | 0.00% | 0.0% |
| Q4 2022 | $202 | -99.9% | 9,611 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $237,000 | +3.5% | 9,611 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $229,000 | +21.8% | 9,470 | +29.9% | 0.00% | +100.0% |
| Q1 2022 | $188,000 | -61.2% | 7,293 | -53.2% | 0.00% | -50.0% |
| Q4 2021 | $484,000 | +132.7% | 15,594 | +103.9% | 0.00% | -75.0% |
| Q4 2020 | $208,000 | – | 7,649 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |